Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients

Alcon Research

Overview

To determine the safety and IOP-lowering ability of a test compound in patients with open-angle glaucoma or ocular hypertension.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Open-Angle Glaucoma Ocular Hypertension

Interventions

Glaucoma therapyDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult subjects of either sex and any race with open-angle glaucoma or ocular hypertension; * logMAR visual acuity not worse than 0.6. Exclusion Criteria: * Clinically relevant ophthalmic or systemic conditions may be excluded.

Locations (1)

Alcon Clinical Trial Sites

Multiple Locations Throughout the US Sponsored by Alcon of, Texas, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.